Difference between revisions of "Example orders for Docetaxel (Taxotere) in prostate cancer"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.'''" to "<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.'''-->") |
Warner-admin (talk | contribs) m (Text replacement - " " to " ") |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | <!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''--> | + | <!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''--> |
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. | Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. | ||
| Line 10: | Line 10: | ||
===Example order set #1=== | ===Example order set #1=== | ||
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1; use non-DEHP (paclitaxel) tubing | *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1; use non-DEHP (paclitaxel) tubing | ||
| − | *Optional: [[Prednisone (Sterapred)]] 5 mg PO | + | *Optional: [[Prednisone (Sterapred)]] 5 mg PO twice per day on days 1 to 21 |
'''21-day cycles''' | '''21-day cycles''' | ||
| − | ====Supportive | + | ====Supportive therapy==== |
*[[Dexamethasone (Decadron)]] 8 mg PO given twice, the evening before and morning of chemotherapy | *[[Dexamethasone (Decadron)]] 8 mg PO given twice, the evening before and morning of chemotherapy | ||
| − | *[[Dexamethasone (Decadron)]] 12 mg PO once 30 minutes prior to chemotherapy | + | *[[Dexamethasone (Decadron)]] 12 mg PO once; 30 minutes prior to chemotherapy |
| − | *Diphenhydramine (Benadryl) 25 to 50 mg IV once 30 minutes prior to chemotherapy | + | *Diphenhydramine (Benadryl) 25 to 50 mg IV once; 30 minutes prior to chemotherapy |
| − | *Famotidine (Pepcid) 20 mg IV over 15 minutes once 30 minutes prior to chemotherapy | + | *Famotidine (Pepcid) 20 mg IV over 15 minutes once; 30 minutes prior to chemotherapy |
Hydration: | Hydration: | ||
| Line 25: | Line 25: | ||
Nursing: | Nursing: | ||
| − | *Patients without central lines: insert peripheral IV before therapy. | + | *Patients without central lines: insert peripheral IV before therapy. Flush peripheral IV with 10 mL 0.9% normal saline after each day's dose of chemotherapy. Remove peripheral IV when therapy is complete. |
| − | *Patients with central lines: access the central venous access device before therapy. | + | *Patients with central lines: access the central venous access device before therapy. Flush central line according to institutional guidelines after each day's dose of chemotherapy. Deaccess device when therapy is complete. |
===Example order set #2=== | ===Example order set #2=== | ||
| Line 34: | Line 34: | ||
'''21-day cycles''' | '''21-day cycles''' | ||
| − | ====Supportive | + | ====Supportive therapy==== |
| − | *[[Dexamethasone (Decadron)]] 10 mg IV once 30 minutes prior to chemotherapy | + | *[[Dexamethasone (Decadron)]] 10 mg IV once; 30 minutes prior to chemotherapy |
| − | *Prochlorperazine (Compazine) 10 mg PO once prior to chemotherapy | + | *Prochlorperazine (Compazine) 10 mg PO once, prior to chemotherapy |
*Due to severe neutropenia, used: [[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2, 24 hours after completion of chemotherapy | *Due to severe neutropenia, used: [[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2, 24 hours after completion of chemotherapy | ||
| Line 44: | Line 44: | ||
Nursing: | Nursing: | ||
| − | *Patients without central lines: insert peripheral IV before therapy. | + | *Patients without central lines: insert peripheral IV before therapy. Flush peripheral IV with 10 mL 0.9% normal saline after each day's dose of chemotherapy. Remove peripheral IV when therapy is complete. |
| − | *Patients with central lines: access the central venous access device before therapy. | + | *Patients with central lines: access the central venous access device before therapy. Flush central line according to institutional guidelines after each day's dose of chemotherapy. Deaccess device when therapy is complete. |
[[Category:Example chemotherapy order sets]] | [[Category:Example chemotherapy order sets]] | ||
Latest revision as of 01:54, 1 June 2023
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
Docetaxel (Taxotere)
Published regimens and references can be found on the prostate cancer page.
Example order set #1
- Docetaxel (Taxotere) 75 mg/m2 IV over 60 minutes once on day 1; use non-DEHP (paclitaxel) tubing
- Optional: Prednisone (Sterapred) 5 mg PO twice per day on days 1 to 21
21-day cycles
Supportive therapy
- Dexamethasone (Decadron) 8 mg PO given twice, the evening before and morning of chemotherapy
- Dexamethasone (Decadron) 12 mg PO once; 30 minutes prior to chemotherapy
- Diphenhydramine (Benadryl) 25 to 50 mg IV once; 30 minutes prior to chemotherapy
- Famotidine (Pepcid) 20 mg IV over 15 minutes once; 30 minutes prior to chemotherapy
Hydration:
- Normal saline IV continuous infusion at 5 mL/H
- Normal saline 25 to 50 mL IV prn flush before and after chemotherapy
Nursing:
- Patients without central lines: insert peripheral IV before therapy. Flush peripheral IV with 10 mL 0.9% normal saline after each day's dose of chemotherapy. Remove peripheral IV when therapy is complete.
- Patients with central lines: access the central venous access device before therapy. Flush central line according to institutional guidelines after each day's dose of chemotherapy. Deaccess device when therapy is complete.
Example order set #2
- Docetaxel (Taxotere) 75 mg/m2 IV over 60 minutes once on day 1; use non-DEHP (paclitaxel) tubing
- Due to toxicity, later dose reduced to Docetaxel (Taxotere) 60 mg/m2 IV over 60 minutes once on day 1
21-day cycles
Supportive therapy
- Dexamethasone (Decadron) 10 mg IV once; 30 minutes prior to chemotherapy
- Prochlorperazine (Compazine) 10 mg PO once, prior to chemotherapy
- Due to severe neutropenia, used: Pegfilgrastim (Neulasta) 6 mg SC once on day 2, 24 hours after completion of chemotherapy
Hydration:
- Normal saline IV continuous infusion at 5 mL/H
- Normal saline 25 to 50 mL IV prn flush before and after chemotherapy
Nursing:
- Patients without central lines: insert peripheral IV before therapy. Flush peripheral IV with 10 mL 0.9% normal saline after each day's dose of chemotherapy. Remove peripheral IV when therapy is complete.
- Patients with central lines: access the central venous access device before therapy. Flush central line according to institutional guidelines after each day's dose of chemotherapy. Deaccess device when therapy is complete.